



Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

S. C. Chen,^{1,2,3} T. C. Sorrell,^{4,5,6} C. C. Chang,^{7,8,9} E. K. Paige,¹⁰ P. A. Bryant^{11,12} and M. A. Slavin^{13,14,15}

¹Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR – Pathology West, Westmead, New South Wales, ²Department of Infectious Diseases, Westmead Hospital, Westmead, New South Wales, ³Sydney Medical School, The University of Sydney, Sydney, New South Wales, ⁴Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, New South Wales, ⁵Centre for Infectious Diseases and Microbiology, Westmead Millennium Institute, Westmead, New South Wales, ⁶Infectious Diseases and Sexual Health Services, Westmead Hospital, Westmead, New South Wales, ⁷Department of Infectious Diseases, Alfred Health and Monash University, Prahran, Victoria, ⁸Centre for Biomedical Research, Burnet Institute, Victoria, ⁹Lewin-Cameron Laboratory, The Doherty Institute for Infection and Immunity, Parkville, Victoria, ¹⁰Department of Infectious Diseases, Alfred Health, Prahran, Victoria, ¹¹Infectious Diseases Unit, Department of General Medicine, The Royal Children's Hospital Melbourne, Melbourne, Victoria, ¹²Clinical Paediatrics Group, Murdoch Children's Research Institute, Melbourne, Victoria, ¹³Department of Infectious Diseases and Infection Control, Peter MacCallum Cancer Centre, East Melbourne, Victoria, ¹⁴Victorian Infectious Diseases Service, The Doherty Institute for Infection and Immunity, Parkville, Victoria, ¹⁵School of Medicine, The University of Melbourne, Melbourne, Victoria.

Keywords

antifungal therapy, candidiasis, cryptococcosis, yeasts, consensus guidelines.

Correspondence

Sharon Chen, Centre for Infectious Diseases and Microbiology Laboratory Services, 3rd Level, ICPMR Building, Westmead Hospital, Darcy Road, Westmead, NSW 2145, Australia.
Email: sharon.chen@health.nsw.gov.au

doi:10.1111/imj.12597

Abstract

Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the *Candida* spp., *Cryptococcus* spp., *Pneumocystis jirovecii* and some lesser-known pathogens. *Candida* species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for 'pre-emptive' or 'diagnostic-driven antifungal therapy' is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of *Pneumocystis jirovecii* are presented in an accompanying article (see consensus guidelines by Cooley *et al.* appearing elsewhere in this supplement).

Introduction

These guidelines discuss management of established invasive yeast infections in adult and paediatric patients in the haematology/oncology setting and in the critically ill patient in intensive care units (ICUs), including the neonatal ICU (NICU). These recommendations update those published previously¹ and are based on antifungal agents currently licensed for use in Australia. Invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections.

Conflict of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance from; or have research or other associations with the organisations listed: Sharon Chen – Gilead, Merck Sharp & Dohme, Pfizer; Monica Slavin – Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Tania Sorrell – Gilead, Merck Sharp & Dohme, Pfizer.

Methodology

Questions asked

In preparing this update, we aimed to address the following questions:

- 1 What is the optimal treatment for systemic yeast infection in adults and children?
- 2 What is the optimal dose and duration of antifungal treatment?
- 3 What investigations and adjunctive therapies improve outcomes?

Search strategy

A literature review was performed using PubMed to identify papers published since 2007 that pertained to the treatment of yeast infections in patients with haematological malignancy, patients of haemopoietic stem cell transplantation (HSCT) and critically ill patients

Table 1 Factors predisposing patients to candidaemia

| Population | Risk factor |
|--|---|
| All patients | Prior abdominal surgery |
| | Intravascular catheters |
| | Parenteral nutrition |
| | Use of broad spectrum antibiotics |
| | Immunosuppression, including corticosteroid therapy |
| | Acute renal failure |
| | Diabetes |
| | Transplantation |
| | Haemodialysis |
| | Pancreatitis |
| | ICU patients |
| <i>Candida</i> colonisation, particularly multifocal | |
| High Acute Physiology and Chronic Health Evaluation II (APACHE II) score | |
| Blood transfusions | |
| Low birth weight and prematurity for neonatal ICU | |
| Necrotising enterocolitis for neonatal ICU | |

in an intensive care setting. Search terms included 'candidiasis', 'candidaemia', '*Candida*', 'cryptococcosis', '*Cryptococcus neoformans*', '*Cryptococcus gattii*', 'yeast and diagnosis, treatment and management'.

Invasive candidiasis and candidaemia

Candida species are the most common cause of invasive yeast infections. Invasive candidiasis (IC) includes blood-stream infection (i.e. candidaemia), deep-seated tissue infection or both. Most studies have focused on candidaemia. In Australia, the incidence of candidaemia (2001–2004) has been estimated at 1.81 cases per 100 000 of population.² *Candida albicans* accounted for approximately 50% of invasive *Candida* isolates, followed by *C. parapsilosis* (20%), *C. glabrata* (15%), *C. tropicalis* (5%), *C. krusei* (4%) and *C. dubliniensis* (2%).² In the NICU, *C. albicans* and *C. parapsilosis* predominate.³ IC, including candidaemia, has a high attributable mortality

(30–71%) and morbidity.^{2,4–7} Multiple risk factors for IC have been identified (see summary in Table 1 and recent reviews by Yapar 2014 and Delaloye and Calandra 2014),^{8,9} with immunocompromised and critically ill patients at particularly high risk. Antifungal therapy should be started early, since treatment delays are associated with worse clinical outcomes and increased mortality (Level III evidence, grade B recommendation).^{10–12}

Laboratory investigations for diagnosis of IC

Blood cultures

Cultures of blood and other clinical specimens remain the cornerstone of diagnosing IC. However, they are insensitive and relatively slow (taking at least 2–3 days),^{13,14} and are positive in only 63–83% of cases of IC^{15,16} and 50% of deep-seated IC.¹⁶

Antifungal susceptibility

Accurate identification of *Candida* spp. is predictive of likely antifungal susceptibility (or resistance) and aids selection of antifungal agents (see Table 2 for common susceptibility patterns of major *Candida* spp.). In Australia, most species, including *C. albicans*, *C. parapsilosis* and *C. tropicalis*, are typically susceptible to fluconazole,²² while those with reduced susceptibility include *C. glabrata* and *C. krusei*.^{17,18,23} The emergence of multi-drug resistance in *C. glabrata*, involving all azoles and echinocandins,^{19,20} is of particular concern. Though the correlation is imperfect, susceptibility testing is often routinely performed against clinically significant isolates (level III-3 evidence, grade C recommendation) and can help guide therapy.

Non-culture approaches

Non-culture-based diagnostics are more sensitive and rapid than culture. However, they do not recover

Table 2 Common antifungal susceptibility patterns of the major *Candida* species^{17–21}

| Species | Amphotericin B | Echinocandins† | FLU | ITRA | VORI‡ |
|------------------------|----------------|----------------|-------------|-----------|--------|
| <i>C. albicans</i> | S | S | S§ | S | S |
| <i>C. glabrata</i> | S | S¶ | S-DD to R†† | S-DD to R | S to R |
| <i>C. krusei</i> | S | S | R | S-DD to R | S to R |
| <i>C. parapsilosis</i> | S | S to R‡‡ | S | S | S |
| <i>C. tropicalis</i> | S | S | S | S | S |

†Susceptibility pattern is similar for all the echinocandins (anidulafungin, micafungin, caspofungin). ‡In general, posaconazole has similar susceptibility patterns as voriconazole. §Resistance of *C. albicans* to fluconazole is approximately 5%. ¶Resistance of *C. glabrata* to the echinocandins appears to be emerging. ††Cross-resistance to azoles occurs in >10% of *C. glabrata* isolates. ‡‡Higher minimum inhibitory concentration values and poor activity against *C. parapsilosis* biofilms. FLU, fluconazole; ITRA, itraconazole; R, resistant; S, susceptible; S-DD, susceptible dose-dependent; VORI, voriconazole.

organisms and may not allow identification to species level. They are also expensive and, in the case of *Candida* PCR assays, not yet standardised. They do have value as complementary tests, as they can increase diagnostic yields and direct diagnostic-driven antifungal therapy.

Candida antigen and antibody detection

The role of serum *Candida* antigen and antibody detection as an early marker of IC is uncertain. The best results have been obtained with a combined mannan/anti-mannan antibody assay (Platelia; Bio-Rad, Marnes-la-coquette, France). While combined testing may be useful in earlier diagnosis of hepatosplenic candidiasis, it is less useful for detecting candidaemia (level II evidence, grade C recommendation),²⁴ and is not currently available in Australia.

β(1,3)-D-glucan detection

The detection in serum of the fungal cell wall component β(1,3)-D-glucan (BDG) for the diagnosis of candidaemia and IC is well studied (see summary by Perfect, 2013),²⁵ but is not used locally due to cost. This assay, however, has been used to guide pre-emptive antifungal therapy. A single-centre study of twice-weekly BDG surveillance among high-risk ICU patients for >3 days reported a positive predictive value (PPV) of 30% for IC (sensitivity 100%, specificity 75%) with a negative predictive value (NPV) of 100%.²⁶ The study also found pre-emptive anidulafungin to be safe and associated with good outcomes. In light of more contemporary data, a re-evaluation of the role of BDG surveillance in Australia and New Zealand is warranted.

Polymerase chain reaction(PCR)-based tests

Nucleic acid amplification assays for *Candida* include those that detect all fungi (e.g. Panfungal PCR²⁷) and those that specifically detect *Candida* spp.; however, these lack methodological standardisation. PCR results can precede positive blood culture results by 1 day to 4 weeks.^{28,29} The combination of blood culture and BDG or PCR tests had superior sensitivities to blood cultures in isolation (79% and 98%, respectively). Hence, these assays may represent useful adjuncts.¹⁶

Identifying patients at high risk of invasive candidiasis

The efficacy of diagnostic-driven antifungal therapy strategies in ICU patients was established by a 2004 study, in which fluconazole – administered to patients with a

predefined *Candida* colonisation index of ≥0.5 based on number of colonised sites³⁰ – significantly decreased the incidence of IC.³¹ Risk factors for invasive candidiasis in the critically ill patient are summarised in Table 1. These patients may benefit from empirical anti-candida therapy (level III evidence, grade C recommendation).

Treatment of invasive candidiasis and candidaemia

When choosing empirical or pre-emptive treatment, knowledge of local epidemiological patterns of IC, the patient's prior therapy and prevalence of antifungal resistance is important. In Australia, the proportion of candidaemia caused by *C. albicans* is relatively high among ICU patients (about 62%) but low among haematology patients (31%).^{2,17,18,21} Total parenteral nutrition (TPN) and central venous catheters (CVCs) are associated with *C. parapsilosis*.

Exposure to fluconazole or broad-spectrum antimicrobials is associated with an increased likelihood of fluconazole-resistant *Candida* spp.^{18,32–34} Similarly, exposure to echinocandins is associated with echinocandin resistance^{35,36} and selection for less susceptible *Candida* spp.³³

When last examined in 2008, the prevalence of fluconazole resistance in *Candida* spp. was stable in Australia.³⁷ Globally, resistance to echinocandins is very uncommon among wild-type *C. albicans*, *C. parapsilosis* and *C. tropicalis*, occurring in just 0.4% of cases of candidaemia in France (2005–2010)³⁶ and 0–0.6% of cases in the Asia-Pacific region (2010–2011).³⁸ However, elsewhere, resistance in *C. glabrata*, with cross-resistance to all echinocandins, has been reported with rates of up to 28%.³⁹ These differences may relate to the varying methodology and criteria employed in different countries to define resistance and/or to differing antifungal usage patterns. In Australia, clinical resistance to the echinocandins appears uncommon.

Initial therapy for invasive candidiasis and candidaemia

Amphotericin B and the triazoles

Studies pre-2008 focused on the use of conventional amphotericin B (amphotericin B deoxycholate [AmB-D]), fluconazole^{40–44} and voriconazole⁴⁵ for the treatment of IC and are reviewed in the previous guidelines.¹ In children and neonates, both azoles and amphotericin B preparations have been shown to be effective for the treatment of IC in open-label studies (see review by Blyth and colleagues, 2007⁴⁶), but studies comparing different

antifungal classes are lacking. The only randomised controlled trial (RCT) comparing azoles to amphotericin B for the treatment of IC in children is a trial of 23 neonates with candidaemia.⁴⁷ Patients were randomised to receive AmB-D 1 mg/kg/day or fluconazole 5 mg/kg/day, with no reported difference in outcomes. A 2010 Cochrane review of the treatment of suspected (prolonged fever and neutropenia) and proven IC identified four RCTs comparing AmB-D with lipid formulations of amphotericin and one trial comparing itraconazole with fluconazole for candidaemia.⁴⁸ No difference in outcomes between the studies was observed but the patient groups were heterogeneous and the studies largely underpowered.

Echinocandins

The efficacy of the echinocandins for the treatment of IC in adults has been assessed by four RCTs comparing: (i) caspofungin versus AmB-D,⁴⁹ (ii) micafungin versus liposomal amphotericin B (L-AMB),⁵⁰ (iii) anidulafungin versus fluconazole⁵¹ and (iv) micafungin versus caspofungin.⁵² Caspofungin and micafungin were not inferior to AmB-D and L-AMB, respectively, but were associated with significantly fewer infusion reactions and nephrotoxicity.^{49,50} Anidulafungin was associated with significantly greater clinical and microbiological efficacy than fluconazole in a modified intention-to-treat population.⁵¹ However, the superior efficacy of anidulafungin should be interpreted with caution, as a possible study bias could not be excluded. Further, fluconazole was given at a dose of 400 mg/day, which may not achieve the required ratio of area under the curve to minimum inhibitory concentration (AUC : MIC) target in all patients with candidaemia.⁵³ A comparative trial of caspofungin at standard doses and micafungin at doses of 100 or 150 mg daily had similar clinical and microbiological outcomes across the three treatment arms in the primary intention-to-treat analysis, as well as similar safety and tolerability.⁵² *C. parapsilosis* has comparatively higher MICs to echinocandins than other *Candida* species, but studies⁵⁴ suggest echinocandin treatment may be successfully used to treat *C. parapsilosis* infections (level III evidence, grade C recommendation). In children with IC, there have been only two RCTs published comparing an echinocandin with another class of antifungal drug.^{55,56} The first study of 106 patients (age range: birth to 16 years) compared micafungin 2 mg/kg with L-AMB 3 mg/kg, and showed similar treatment success (73% and 76%, respectively). The second study involving 32 neonates compared caspofungin 2 mg/kg with AmB-D 1 mg/kg, and showed a superior composite success rate with caspofungin (87% vs 42%, respectively). However, this endpoint included discontinuation due to adverse events, and both studies showed increased

infusion-related adverse events and nephrotoxicity (albeit temporary) in the amphotericin groups.

Several authors have also examined the pooled results of antifungal treatment studies. One review compared the outcomes of 1195 patients receiving AmB-D, L-AMB, fluconazole, voriconazole and the echinocandins.⁵⁷ A multivariate analysis found that only CVC removal and receipt of an echinocandin were associated with survival and clinical success.⁵⁷ However, this analysis has been criticised on the basis of the number of patients excluded due to lack of outcome data and the prolonged time period over which the studies were conducted (1989–2006).^{58–60} Conversely, the analyses of Gafter-Gvili *et al.* 2008⁴⁴ and Mills *et al.* 2009⁶¹ of RCTs assessing the treatment of IC and candidaemia over a similar time period, did not show an improvement in all-cause mortality for patients receiving echinocandins compared to other antifungals. However, Gafter-Gvili *et al.* 2008 did conclude that echinocandins and AmB-D had a lower rate of microbiological failure than fluconazole.⁴⁴ There have been no meta-analyses of echinocandin use in children.

Evidence-based treatment recommendations for adults

The superiority of echinocandins over other agents for the treatment of candidaemia has not been conclusively proven, although they are associated with fewer adverse events than AmB-D and fluconazole.⁴⁴ Based on the analysis of Andes *et al.* 2012⁵⁷ and the reduced propensity for adverse events,⁴⁴ echinocandins received the highest level of recommendation for the initial treatment of candidaemia in the ESCMID guidelines,⁶² as they do in the current guideline (see Table 3 for a summary of recommendations and Table 4 for dosing guidance).

Initial therapy with an echinocandin is favoured in the critically ill or haemodynamically unstable patient (level III evidence, grade B recommendation), as well as in the setting of neutropenia (level IV evidence, grade D recommendation), or where a biofilm infection or azole resistance is suspected (level IV evidence, grade D recommendation). An analysis of anidulafungin versus fluconazole supports this approach.⁵¹ Kett *et al.*, 2011 evaluated outcomes in 163 patients with severe sepsis (in ICU or with Apache II scores >15) and a better global response was observed at the end of treatment with anidulafungin compared to fluconazole, with a trend to lower mortality at day 14 (10% vs. 20%, $P = 0.08$), although day 28 mortality (20% vs. 24%) was not significantly different.⁶³ This study was a post-hoc analysis and not designed to examine the question of superiority in critically ill patients. The results, therefore, are not definitive. An analysis of outcomes in Spanish critical

Table 3 Recommended antifungal therapy for adult patients with candidaemia or invasive candidiasis†

| Candida spp. | Clinical scenario/patient type | Antifungal agent | | | | | | |
|---|--|------------------|--------------|---------------|-------------|------------|-----------------|-------|
| | | Azole | | Echinocandin‡ | | | Amphotericin B§ | |
| | | Fluconazole | Voriconazole | Anidulafungin | Caspofungin | Micafungin | L-AMB | AmB-D |
| Unknown organism or species | Critically ill OR neutropenic OR risk factors associated with azole resistance | NR | C | A | A | A | B | C |
| | Risk factors associated with echinocandin resistance and one of the following: critically ill OR neutropenic | NR | C | NR | NR | NR | B | C |
| | Clinically stable with no risks for azole or echinocandin resistance | B | C | A | A | A | C | C |
| Fluconazole susceptible <i>Candida</i> spp. | Critically ill OR neutropenic | B | B | A | A | A | B | C |
| | Clinically stable | A | B | A | A | A | B | B |
| <i>C. glabrata</i> | Critically ill | NR | NR | A | A | A | B | C |
| | Clinically stable | B¶ | B¶ | A | A | A | B | C |

†Most recommendations in children, unless otherwise stated, would be considered Grade C at best, due to the paucity of dedicated paediatric randomised data. ‡There are limited data about the pharmacokinetics, safety and efficacy of anidulafungin in children. If an echinocandin is required, caspofungin or micafungin would be favoured. §Conventional amphotericin B-associated toxicity is less common in children than in adults. It should be considered at the same level as lipid formulations in children with candidaemia or invasive candidiasis. ¶Provided *C. glabrata* isolate is not azole resistant. AmB-D, amphotericin B deoxycholate; L-AMB, liposomal amphotericin B; NR, not recommended.

care patients suggests appropriate treatment, as well as catheter removal, improves survival.⁶⁴ In the setting of endophthalmitis and central nervous system (CNS) infection, echinocandins should not be used due to poor drug penetration (level III evidence, grade C recommendation).⁶⁵ See Table 5 for treatment recommendations when infection involves difficult sites.

There is a role for initial therapy with fluconazole where the patient is clinically stable and the isolate is

likely to be susceptible to fluconazole (level II evidence, grade B recommendation). The recommended loading dose of fluconazole is 800 mg (12 mg/kg) followed by 400 mg/day (6 mg/kg/day).⁹⁸ However, this may be suboptimal in some patients due to high *Candida* MIC or patient pharmacokinetics. While optimisation of AUC : MIC > 25 is recommended (level III evidence, grade C recommendation), fluconazole levels are not commonly performed in routine practice.^{72,99}

Table 4 Recommended doses of licensed antifungal agents for *Candida*†

| Agent | Preparation | Recommended dose adults | Recommended dose children | Recommended dose neonates |
|------------------------------|-------------|---|--|--|
| Anidulafungin | IV | 200 mg, daily for 24 h then 100 mg, daily | 3 mg/kg loading dose on day 1 then 1.5 mg/kg, daily | 3 mg/kg loading dose on day 1 then 1.5 mg/kg, daily |
| Caspofungin | IV | 70 mg/day for 24 h then 50 mg, daily | 50 mg/m ² , daily | 25 mg/m ² , daily |
| Micafungin | IV | 100 mg, daily | 2–4 mg/kg, daily | 10 mg/kg, daily |
| Amphotericin B deoxycholate | IV | 0.6–1 mg/kg, daily | 0.7–1 mg/kg, daily | 0.5–1 mg/kg, daily |
| Liposomal amphotericin | IV | 3 mg/kg, daily | 3 mg/kg, daily | 3 mg/kg, daily |
| Amphotericin B lipid complex | IV | 3–5 mg/kg, daily | 5 mg/kg, daily | 5 mg/kg, daily |
| Fluconazole | Oral/IV | 12 mg/kg, daily for 24 h then 6–12 mg/kg, daily | 12 mg/kg, daily | 25 mg/kg loading dose on day 1, then 12 mg/kg/day |
| Voriconazole | Oral/IV | 6 mg/kg, 12 hourly for first 24 h then 4 mg/kg, 12 hourly | 9 mg/kg, 12 hourly day 1 then 8 mg/kg, 12 hourly + TDM | 4–6 mg/kg, 12 hourly (data from case series, not PK studies) |
| Itraconazole | Oral | | 2.5 mg/kg, 12 hourly + TDM | No data |

†Also see full approved Product Information for individual antifungal agents. IV, intravenous; PK, pharmacokinetic; TDM, therapeutic drug monitoring.

Table 5 Treatment of invasive candidiasis in difficult sites†

| Clinical setting | Recommended agents | Alternative agents | Comments |
|--|--|--|---|
| Hepatosplenic (chronic disseminated) candidiasis | Fluconazole 400 mg, daily (6 mg/kg) if stable L-AMB 3–5 mg/kg, daily or AmB-D 0.5–0.7 mg/kg, daily if unstable, followed by fluconazole | An echinocandin followed by fluconazole | <ul style="list-style-type: none"> • Prolonged neutropenia is a risk factor⁶⁶ • Continue antifungal therapy while receiving immunosuppression and until imaging abnormalities resolve (usually at least 6 months)^{67–70} • There is limited evidence supporting the use of corticosteroids for persisting fevers in this setting^{67,70} |
| CNS candidiasis (meningitis or intracerebral abscesses ⁷¹) | L-AMB 3–5 mg/kg, daily ± 5-flucytosine 25 mg/kg, 6-hourly followed by fluconazole 400–800 mg, daily | Fluconazole 400–800 mg, daily (6–12 mg/kg) | <ul style="list-style-type: none"> • Continue therapy until at least 4 weeks after resolution of radiological signs and neurological symptoms^{72,73} • Remove intraventricular devices^{71,72} • There are limited data on posaconazole, voriconazole or echinocandins for CNS candidiasis^{74–77} |
| Ocular candidiasis | AmB-D 0.7–1 mg/kg, daily <i>plus</i> 5-fluorouracil 25 mg/kg, 6-hourly ^{62,72} or fluconazole 400–800 mg, daily (6–12 mg/kg) | L-AMB 3–5 mg/kg, daily or voriconazole 6 mg/kg, 12-hourly for two doses then 3–4 mg/kg, 12-hourly ^{78–80} | <ul style="list-style-type: none"> • Treat for 4–6 weeks and until ocular lesions have resolved^{72,81} • Consider intravitreal antifungal therapy or surgical vitrectomy in the presence of vitritis • Echinocandins are not recommended due to concerns regarding their ocular penetration⁸¹ |
| <i>Candida</i> osteomyelitis | Fluconazole 400 mg, daily (6 mg/kg) or L-AMB 3–5 mg/kg, daily followed by fluconazole ^{82–86} | An echinocandin followed by fluconazole | <ul style="list-style-type: none"> • Treat for 6–12 months^{82,83,87} • Adjunctive surgery may be required⁷² |
| <i>Candida</i> septic arthritis | Surgical intervention is essential ⁷² Fluconazole 400 mg, daily (6 mg/kg) or L-AMB 3–5 mg/kg, daily followed by fluconazole ^{84,85,88–90} | An echinocandin followed by fluconazole, or voriconazole ^{62,72} | <ul style="list-style-type: none"> • Treat for a minimum of 6 weeks • Removal of the prosthesis is usually required in prosthetic joint infections; if not removed, long-term suppressive therapy is recommended^{62,72} |
| <i>Candida</i> endocarditis | Surgical intervention is recommended ^{62,72} L-AMB 3–5 mg/kg, daily ± 5-fluorouracil or an echinocandin ^{91–95} | Fluconazole can be used as suppressive therapy but should not be used alone in initial treatment ^{96,97} | <ul style="list-style-type: none"> • Treat for at least 6 weeks^{62,72} • For those who do not undergo valvular surgery, use lifelong suppressive fluconazole 400–800 mg, daily (6–12 mg/kg) • Surgery is particularly important in prosthetic valve endocarditis^{62,72} |
| Symptomatic <i>Candida</i> cystitis or pyelonephritis | Cystitis: fluconazole 200 mg, daily Pyelonephritis: fluconazole 200–400 mg, daily | AmB-D ± flucytosine, or flucytosine alone Echinocandins reserved for resistance or intolerance | <ul style="list-style-type: none"> • Continue therapy for 14 days • Amphotericin B bladder irrigation now infrequently used |
| Candidal urinary tract fungal ball | Fluconazole 200–400 mg, daily or AmB-D 0.5–0.7 mg/kg, daily ± flucytosine 25 mg/kg, 6-hourly | | <ul style="list-style-type: none"> • Surgery often required ± local irrigation using endoscopic methods |

AmB-D, amphotericin B deoxycholate; CNS, central nervous system; CVC, central venous catheter; L-AMB, liposomal amphotericin B. †All recommendations are grade D, based on level 4 evidence.

Evidence-based treatment recommendations for children and neonates

The principles guiding the choice of antifungal agent in children are similar to those discussed for adults – in short, give due regard to local epidemiology and severity of illness. No adequately powered comparative trials have been performed in the paediatric and neonatal setting. Recommendations about treatment choice are therefore

derived from the limited paediatric data, adult studies and expert opinion.

Antifungal dosing cannot be extrapolated from adult studies, as children have a greater volume of distribution, higher drug elimination and different toxicity profiles, and these variables change during childhood (see Table 4 for dose recommendations). There has been a paucity of specific pharmacokinetic studies in children and neonates. A study of fluconazole in immunocompromised

children over 5 years showed that doubling the dose to 12 mg/kg/day was required for equivalence to the adult dose (400 mg/day), due to rapid drug elimination.¹⁰⁰ In neonates, slower elimination of fluconazole necessitates increased intervals between doses and a loading dose has been recommended to achieve therapeutic levels on day 1.^{101,102} Voriconazole also needs higher comparative dosing in children (who have linear elimination of the drug) than in adults (non-linear), as demonstrated in a group of immunocompromised children aged 2–12 years where a dose of 8 mg/kg twice daily was shown to be equivalent to an adult dose of 4 mg/kg twice daily.¹⁰³ Itraconazole, conversely, needs no dose adjustment with 2.5 mg/kg twice daily shown to be effective in paediatric HIV patients with oropharyngeal candidiasis.¹⁰⁴ Amphoterin B, in both its conventional and lipid formulation, has similar pharmacokinetics in neonates and children as in adults with lipid formulation doses of 2.5–5 mg/kg daily recommended.¹⁰⁵ The few recent pharmacokinetic studies in children have focused on the echinocandins. Caspofungin has a more comparable AUC to adult dosing in both children and neonates when dosed using body surface area rather than weight, with 50 mg/m²/day in children aged 2–11 years equivalent to an adult dose of 50 mg/day.^{103,106} Anidulafungin is faecally excreted so is an attractive option in patients with hepatic or renal failure. It needs no dose adjustment, with 1.5 mg/kg/day in immunocompromised children and neonates equivalent to an adult dose of 100 mg/day.^{107,108} Micafungin has high drug elimination in young patients and in immunocompromised children aged 2–12 years, requiring doses of 4 mg/kg/day for adult equivalence.⁹⁸ Doses of 10 mg/kg/day are required in neonates to ensure CNS penetration.¹⁰⁹

***Candida glabrata*: a problematic organism**

C. glabrata is prevalent in many regions¹¹⁰ and has potential to be cross-resistant to both the triazoles and echinocandins.^{35,38,110} This is due to increased transporter genes,¹¹¹ increased expression of efflux pumps¹¹² and the propensity for biofilm formation.¹¹³ Further, *C. glabrata* exists in a haploid state and hence is more prone to mutations.¹¹⁴ Indeed, some features of resistant *C. glabrata* may allow for increased virulence.¹¹⁵ Treatment, therefore, may be a challenge. These data argue strongly for rapid identification of the species causing the candidaemia, as well as antifungal susceptibility testing of all isolates.³⁵

Treatment of invasive candidiasis in difficult sites

Treatment recommendations for hepatosplenic, central nervous system (CNS), ocular, bone and joint, endocar-

ditis and urinary tract candidiasis are summarised in Table 5.

Candida spp. are the most common causes of fungal endocarditis,¹¹⁶ which has a higher mortality than non-fungal endocarditis.⁹¹ Candidaemia is complicated by endocarditis in up to 17.7% of cases when transoesophageal echocardiogram (TOE) is routinely performed.⁹²

In the absence of surgery, increased mortality rates have been seen in some cohorts^{116,117} but not in others,^{91,92} although most data was obtained prior to the availability of the echinocandins. Combined surgical and antifungal therapy is the optimal treatment and should be employed where possible. There have been reports of successful medical treatment with caspofungin in a small number of patients in whom surgical intervention was not possible.^{92,93} The potential efficacy of echinocandin drugs is increasingly recognised in the treatment of fungal endocarditis due to their biofilm penetration.^{118–120}

Duration and route of administration of antifungal therapy

There are no prospective data on the optimal duration of therapy for IC¹²¹ and recommendations are largely based on expert opinion in both adults and children. The identification and management of ongoing infective foci, and of end-organ complications of IC, are important to maximise the long-term success of therapy. Several important ancillary management decisions should be considered (these are summarised in Table 6). For candidaemia with deep-tissue infection, treatment with systemic antifungal agents for 14 days following the last positive sterile site culture and resolution of clinical features of infection is recommended,^{62,72} this approach has been adopted in most comparative trials (level III evidence, grade C recommendation).^{45,50,52,131} Expert opinion recommends similar durations for peritonitis, but 6 weeks or longer for difficult-to-treat deep foci such as endocarditis, endophthalmitis, mediastinitis or osteomyelitis (grade D recommendation).⁷²

The intravenous route is preferred for the initiation of antifungal therapy to ensure adequate blood and tissue levels are achieved. Following satisfactory clinical and microbiological response, changing from intravenous to oral antifungal therapy is appropriate, assuming susceptibility to the oral agent and a functioning gastrointestinal tract (level III evidence, grade C recommendation).¹³²

Cryptococcosis

Cryptococcosis is predominantly caused by two species, *Cryptococcus neoformans* (serotypes A [*C. neoformans* var. *grubii*], D [*C. neoformans* var. *neoformans*] and AD) and

Table 6 Recommendations for ancillary management measures in candidaemia

| Recommendation | Grade | Comment |
|---|-------|---|
| Early removal of vascular catheters where possible ^{62,72,122} | B | Removal of catheters, ideally within 48 h, may have a mortality benefit ^{18,64,123} and expedites clearance; ¹²⁴ it is particularly important in <i>C. parapsilosis</i> infection, which is usually catheter associated |
| When catheter removal is not possible, an echinocandin ^{118,125} or L-AMB ^{119,126} is recommended for biofilm penetration | D | |
| Follow-up blood cultures are advised to ensure clearance of infection ⁷² | C | Persistent or breakthrough candidaemia may suggest a persistent infective focus or a resistant organism; ^{127,128} ocular candidiasis is correlated with longer duration of candidaemia ⁷⁸ |
| Ophthalmological examination should be routinely performed in all patients within the first week of antifungal therapy ^{72,129} | C | Findings consistent with ocular candidiasis, often chorioretinitis, are found in 10–20% of patients with candidaemia ^{78,130} |
| Serial ophthalmological examinations may be required | C | In persistent candidaemia, a repeat ophthalmological examination may detect ocular candidiasis ^{78,129} |
| Echocardiography should be performed in patients with persistent candidaemia or those with risk factors for endovascular infection ^{91,92,116} | C | Risk factors for endocarditis include pre-existing valve disease, ¹¹⁶ CVC access ⁹² and persistently positive blood cultures for <i>Candida</i> spp. ⁹¹ |

Cryptococcus gattii (serotypes B and C).¹³³ The predilection of *Cryptococci* for the central nervous system (CNS) can lead to life-threatening meningoencephalitis.¹³⁴

Antifungal susceptibility of *Cryptococcus*

MICs of amphotericin B, 5-flucytosine, fluconazole, voriconazole and posaconazole have been reported.^{135,136} However, routine susceptibility testing is not recommended (level IV evidence, grade D recommendation), as primary resistance to antifungal drugs is uncommon in Australia.¹³⁷ There are no standardised MIC breakpoints and MIC levels have not been shown to correlate with clinical outcomes. As molecular type VGI predominates (overwhelmingly) in Australia, routine susceptibility

testing is not indicated (level IV evidence, grade D recommendation).¹³⁸

Diagnosis of cryptococcosis

Based on recent studies, laboratory investigations in patients with cryptococcal infection in any site – except in patients with small pulmonary cryptococcomas and negative serum cryptococcal antigen (CrAg) tests – should include blood cultures, cerebrospinal fluid (CSF) examination and an assessment of patient risk factors (including CD4/CD8 lymphocyte counts, HIV antibody status and other causes of immunosuppression) (level IV evidence, grade D recommendation).^{139,140}

Management of cryptococcosis

Initial management of cryptococcosis requires both antifungal therapy and control of raised intracranial pressure (ICP). Measuring the opening pressure via lumbar puncture is important (level III evidence, grade C recommendation), as raised ICP is associated with increased morbidity and mortality.¹³⁹ The only RCTs of antifungal therapy in cryptococcosis have been conducted in HIV-infected patients with *C. neoformans* meningitis. The choice of initial antifungal regimen depends on the site and severity of infection and the immune status of the host. Antifungal therapeutic recommendations for adults and children are summarised in Table 7. Where relevant, doses of immunosuppressive agents should be reduced slowly¹³⁹ while balancing the risk of developing cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS).

Treatment of *C. neoformans* infection

Meningoencephalitis

Combination therapy with AmB-D 1 mg/kg/day and 5-FC 100 mg/kg/day is associated with superior outcomes.¹⁴² Liposomal amphotericin B (L-AMB) may be used in place of AmB-D at 3–6/kg/day (level II evidence, grade B recommendation).^{143,144} The lower dose (3 mg/kg) may be used when administered concurrently with 5-FC.¹⁴⁵

In HIV-infected individuals, a repeat lumbar puncture to check for CSF sterility is prudent prior to switching from induction to consolidation antifungal therapy and prior to commencing combination antiretroviral therapy (cART) (level III evidence, grade C recommendation).^{146,147} Guidance on consolidation and maintenance therapy is summarised in Table 7 and discussed in more detail elsewhere.¹³⁹

L-AMB and AmB-D are both considered Category B drugs during pregnancy; concurrent 5-flucytosine

Table 7 General recommendations for the antifungal treatment of central nervous system and pulmonary cryptococcosis due to *C. neoformans* and *C. gatti* (adapted from Perfect *et al.*, 2010¹³⁹ and Chen *et al.*, 2013¹⁴¹)

| Host risk group or clinical setting | First-line antifungal therapy (level of evidence/grade of recommendation) | Alternative agents for antifungal therapy (level of evidence/grade of recommendation) | Comments (level of evidence/grade of recommendation) |
|---|---|--|--|
| <i>Cryptococcus neoformans</i> | | | |
| CNS infection | | | |
| HIV-infected individuals | Induction therapy: L-AMB 3 mg/kg, daily (or AmB-D 1 mg/kg, daily) plus 5-flucytosine 100 mg/kg, daily for 2 weeks (II, B) Consolidation therapy: fluconazole 400 mg, daily (6 mg/kg, daily) for 8 weeks (II, B) Maintenance therapy: fluconazole 200 mg, daily for ≥ 1 year (II, B) | Induction therapy: L-AMB 3 mg/kg, daily (or AmB-D 1.0 mg/kg, daily) alone for 4–6 weeks (III, B) OR L-AMB 3 mg/kg, daily (or AmB-D 1 mg/kg, daily) plus fluconazole (III, B) ¹⁹ OR 5-flucytosine 100 mg/kg, daily plus fluconazole 800 mg, daily (III, B) Maintenance therapy: itraconazole 400 mg, daily for at least 12 months (II, C) ⁶⁹ | In patients with impaired renal function, L-AMB is preferred (IV, D). Induction therapy with fluconazole alone is not recommended due to suboptimal clinical response (III, C). ^{17,21} Where there is no alternative, then higher doses of fluconazole (800 to 1200 mg, daily) may be used, either as monotherapy (II, C) or, if possible, in combination with 5-flucytosine (II, C) |
| Organ transplant patients | Induction therapy: L-AMB 3 mg/kg, daily (or ABLC 5 mg/kg, daily) plus 5-flucytosine 100 mg/kg, daily for 2 weeks (III, C) Consolidation therapy: fluconazole 400–800 mg, daily for 8 weeks (III, B) Maintenance therapy: fluconazole 200–400 mg, daily for 12 months | Induction therapy: L-AMB 6 mg/kg, daily or ABLC 5 mg/kg, daily or AmB-D 0.7–1.0 mg/kg, daily for 4–6 weeks (III, C) | L-AMB is the preferred amphotericin B formulation as induction therapy (IV, D) ⁶⁹ |
| Non-HIV infected, non-transplant hosts | Induction therapy: L-AMB 3 mg/kg, daily (or AmB-D 0.7–1.0 mg/kg, daily) plus 5-flucytosine 100 mg/kg, daily for ≥ 4 weeks (III, C) Consolidation therapy: fluconazole 400–800 mg, daily for 8 weeks (III, C) Maintenance therapy: fluconazole 200 mg, daily for 6–12 months (III, C) | Induction therapy: L-AMB 3 mg/kg, daily or AmB-D 0.7–1.0 mg/kg, daily for ≥ 6 weeks (III, C) | Although the term ‘maintenance’ therapy is used, therapy aims to be curative |
| Children: immunocompromised | Induction therapy: L-AMB 3 mg/kg, daily (or AmB-D 1 mg/kg, daily) plus 5-flucytosine 100 mg/kg, daily for 2 weeks Consolidation therapy: fluconazole 12 mg/kg, daily for 8 weeks Maintenance therapy: fluconazole 6 mg/kg, daily 6–12 months | Induction therapy: L-AMB 3 mg/kg, daily plus 5-flucytosine 100 mg/kg, daily for 2 weeks | An LP should be done at the end of induction to ensure CSF sterility and the induction phase should be continued until sterility of CSF is achieved |
| Children: immunocompetent | Induction therapy: AmB-D 1.0 mg/kg, daily plus 5-flucytosine (100 mg/kg, daily) for 4 weeks Consolidation therapy: fluconazole 12 mg/kg, daily for 8 weeks Maintenance therapy: fluconazole 6 mg/kg 6–12 months | Induction therapy: L-AMB (5 mg/kg, daily) plus 5-flucytosine (100 mg/kg, daily) for 4 weeks | An LP should be done at the end of induction to ensure CSF sterility and the induction phase should be continued until sterility of CSF is achieved |
| Pulmonary cryptococcosis without CNS involvement | | | |
| Immunocompetent patients with mild disease | Fluconazole 400 mg, daily for 6–12 months (III, C) | — | — |
| Immunosuppressed patients and immunocompetent patients with severe lung disease | Same as for CNS disease Duration of therapy 12 months (III, C) | — | — |
| <i>Cryptococcus gatti</i> | | | |
| CNS infection | | | |
| | Induction: L-AMB 3 mg/kg, daily (or AmB-D 0.7–1.0 mg/kg, daily) plus 5-flucytosine 100 mg/kg, daily for at least 6 weeks (IV, D) Consolidation/maintenance: Fluconazole 400 mg, daily for 12–18 months (III, C) ¹⁴¹ | — | Induction therapy with fluconazole monotherapy is not recommended due to a high probability of treatment failure (IV, D) ¹⁴¹ Surgical excision of mass lesions where appropriate (IV, D) |
| Pulmonary cryptococcosis without CNS involvement | Induction therapy: L-AMB 3 mg/kg, daily (or AmB-D 0.7–1.0 mg/kg, daily) plus 5-flucytosine (100 mg/kg, daily) for 2 weeks (IV, D) Consolidation/maintenance therapy: Fluconazole 400 mg, daily for 6–12 months (IV, D) ¹⁴¹ | — | For mild lung disease in the absence of immunosuppression, fluconazole monotherapy 400–800 mg, daily for 6–12 months may be considered ¹⁴¹ |

L-AMB, liposomal amphotericin B; AmB-D, amphotericin B deoxycholate; ABLC, amphotericin B lipid complex; LP, lumbar puncture; CSF, cerebrospinal fluid; CNS, central nervous system.

(Category C) should be discussed. Fluconazole (Category C) should be avoided until after delivery (level IV evidence, grade D recommendation).¹⁴⁸

There is a lack of studies addressing treatment in children; recommendations are extrapolated from adult studies and represent expert opinion.¹⁴⁹

Pulmonary infection

Immunocompetent patients with mild or no symptoms may be treated with fluconazole 400 mg/day, for 6–12 months (level III evidence, grade C recommendation).^{139,150,151} Those with immunosuppression, large

cryptococcomas or diffuse infiltrates should be treated as for cryptococcal meningitis (level III evidence, grade C recommendation).

Non-meningeal, non-pulmonary cryptococcosis

There are no clinical trial data on the treatment of patients with non-meningeal, non-pulmonary cryptococcosis. Other guidelines suggest that in the absence of immune suppression, fluconazole 400 mg/day (6 mg/kg/day) for 6–12 months may be used (level IV evidence, grade D recommendation). In immunosuppressed patients, treatment doses and duration are in line with those presented for cryptococcal meningitis.

Treatment of *C. gattii* infection

There are no clinical trial data on the management of *C. gattii* infection; recommendations are based on expert opinion and case series (level IV evidence, grade D recommendation). The IDSA guidelines recommend similar induction regimens and durations of therapy to those used for *C. neoformans*.¹³⁹ However, a recent Australian retrospective case series of 86 cases of *C. gattii* (largely CNS cryptococcosis), indicated that induction therapy with amphotericin B and 5-flucytosine for at least 6 weeks and a prolonged total duration of therapy (at least 12–18 months) enabled clinical cure (level IV evidence, grade D recommendation).¹⁴¹ For disease restricted to the lung, combination amphotericin B and 5-flucytosine is recommended for 2 weeks followed by fluconazole, although in mild lung disease without immunosuppression, fluconazole monotherapy may also achieve cure (level IV evidence, grade D recommendation).

Adjunctive management of cryptococcosis

Raised intracranial pressure

Many patients with cryptococcal meningitis have raised ICP (defined as a CSF pressure of >25 cm H₂O).¹⁵² Early detection and reduction of raised ICP is critical, as this has been associated with increased mortality and neurological sequelae.^{140,152–154} Therapeutic LPs should be undertaken at daily intervals until the CSF pressure is ≤20 cm H₂O or <50% of the initial opening pressure.^{139,152,155,156} If repeated LPs fail to control CSF pressure, CSF shunts or drains are recommended (level IV evidence, grade D recommendation), although the optimal timing and efficacy of these procedures have not been examined systematically.^{157,158}

Surgical management

Cerebral and pulmonary cryptococcomas may occur in both *C. neoformans* and *C. gattii* disease. Lesions caus-

ing mass effects, such as pressure on vital structures or bleeding, should be excised where practicable (level IV evidence, grade D recommendation).

Exogenous interferon (INF)

There have been two randomised studies of exogenous INF-gamma as adjuvant therapy for cryptococcal meningitis. One showed a non-significant trend towards improved CSF clearance of cryptococci¹⁵⁹ and the other demonstrated faster rates of fungal clearance but no change in mortality.¹⁶⁰ Further evidence is required before recommendations for the use of INF-gamma in cryptococcosis can be made.

Corticosteroid and other therapies

Steroids have been used, apparently successfully, in patients with cryptococcal meningitis – mostly in *C. gattii* infections and cases of C-IRIS or CNS mass lesion with significant oedema.^{141,161} An international multi-centre study of cryptococcal meningitis in 800 HIV-infected patients receiving 6 weeks of adjunctive therapy with dexamethasone is currently underway (ISRCTN59144167). Acetazolamide is not recommended, as it has been associated with adverse outcomes in *C. neoformans* cryptococcal meningitis.¹⁶²

Cryptococcal persistence and relapse

In cryptococcal meningitis, persistent infection may be defined as persistently positive CSF cultures after 4 weeks of an effective antifungal regimen.¹³⁹ In such cases, prolongation of induction therapy should be considered. Similarly, re-induction therapy should be given to those with microbiological relapse and a higher consolidation dose of fluconazole (600–800 mg/day) is recommended (level IV evidence, grade D recommendation). Voriconazole (200–400 mg BD)¹⁶³ or posaconazole (200 mg QID or 400 mg BD)¹⁶⁴ for 10–12 weeks may be suitable for salvage therapy (level IV evidence, grade D recommendation). There are no studies comparing the efficacy of the newer azoles with that of fluconazole. Antifungal susceptibility testing is recommended in microbiological relapse (level IV evidence, grade D recommendation).

Cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS)

C-IRIS has been reported in apparently normal hosts with *C. gattii* infection, particularly those with a lower CD4 + T-cell count, brain involvement and concurrent

Table 8 Antifungal therapy for rare yeast infections by organism group

| Organism(s) | Preferred antifungal agents | Strength of recommendation | Comments |
|----------------------------|---------------------------------|----------------------------|---|
| <i>Geotrichum candidum</i> | Amphotericin B† ± 5-flucytosine | C-III | No data for fluconazole (high MICs); low MIC values for voriconazole, limited human data ^{169–171} |
| <i>Kodameae ohmeri</i> | Amphotericin B† | C-III | Most (though limited clinical experience with amphotericin B†); ^{172,173} elevated azole MICs for some isolates ^{174,175} |
| <i>Rhodotorula</i> spp. | Amphotericin B† ± 5-flucytosine | B-III | <i>In vitro</i> susceptibility only to these two agents; <i>in vitro</i> resistance to all azoles and echinocandins ^{176,177} |
| <i>Trichosporon</i> spp. | Voriconazole | C-III | Preferred therapy but scarce data; <i>in vitro</i> resistance to fluconazole, 5-flucytosine and amphotericin B† reported ^{178,179} |

†Refers to amphotericin B deoxycholate and its lipid formulations. MIC, minimum inhibitory concentration.

brain-meninges-lung involvement.¹⁴¹ It also occurs in solid-organ transplant patients.¹⁶⁵ However, C-IRIS is best studied in AIDS-associated cryptococcal meningitis, where it presents as clinical worsening or an apparently new presentation of cryptococcal disease after commencement of cART.^{166,167}

There are no prospective clinical trials to help guide the management of C-IRIS but in symptomatic CNS infection, especially in the presence of mass effect, corticosteroids have been used. Recommended doses are 0.5–1.0 mg/kg/day of prednisone equivalent over 2–6 weeks with gradual tapering of the dose (level IV evidence, grade D recommendation). Antifungal therapy should be continued.

Rare yeast infections

Rarer yeast pathogens include *Malassezia*, *Rhodotorula*, *Trichosporon*, *Geotrichum*, *Kodameae* and *Saccharomyces* species. Common colonisers of the skin and mucosal surfaces, these pathogens rarely result in invasive infections except in severely immunosuppressed individuals. DNA sequencing is required for identification to species level. Rare yeast infections represent 1.1–5.1% of fungal isolates in Europe.¹⁶⁸ The incidence of rare yeast infections is not known in Australia but is likely to be low.

There are no trial data to guide treatment and MIC breakpoints are lacking. In general, all these rare yeast species (except *Saccharomyces* and *Kodameae ohmeri*) are regarded as intrinsically resistant to the echinocandins.¹⁶⁸ The European Society for Clinical Microbiology and

Infectious Diseases (ESCMID)/ECMM Joint Committee has formulated guidelines for first-line antifungal therapy.¹⁶⁸ These are summarised in Table 8.

Implications for research

Continued epidemiological surveillance studies are required to understand the evolution of yeast ecology and antifungal resistance. Improved diagnostics and treatment strategies to direct antifungal therapy in high-risk ICU patients are necessary.

Conclusion

Invasive yeast infections are a significant cause of morbidity and mortality in immunocompromised patients and the critically ill host. The usefulness of available tests to facilitate early diagnosis and diagnostic driven treatment is explored here. When choosing empirical or pre-emptive treatment, knowledge of local epidemiological patterns, a patient's prior therapy and prevalence of antifungal resistance is important. Evidence-based recommendations to help guide choice and dose of antifungal agent have been provided with consideration of ancillary management measures, where relevant.

Acknowledgements

The authors would like to thank members of ALLG, ASID and ANZCHOG for their review of the draft document, and Dr Candice O'Sullivan from Wellmark Pty Ltd for her assistance in preparing the manuscript for submission.

References

- Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD *et al.* Recommendations for the treatment of established fungal infections. *Intern Med J* 2008; **38**: 496–520.
- Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D *et al.* Active surveillance for candidemia, Australia. *Emerg Infect Dis* 2006; **12**: 1508–16.
- Barton M, O'Brien K, Robinson JL, Davies DH, Simpson K, Asztalos E *et al.* Invasive candidiasis in low birth weight

- preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. *BMC Infect Dis* 2014; **14**: 327.
- 4 Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. *Pharmacotherapy* 2010; **30**: 361–8.
 - 5 Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. *Eur J Clin Microbiol Infect Dis* 2006; **25**: 419–25.
 - 6 Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. *PLoS ONE* 2013; **8**: e59373.
 - 7 Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. *Crit Rev Microbiol* 2010; **36**: 1–53.
 - 8 Yapar N. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag* 2014; **10**: 95–105.
 - 9 Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. *Virulence* 2014; **5**: 161–9.
 - 10 Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin Infect Dis* 2006; **43**: 25–31.
 - 11 Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive *Candida* species infections. *J Antimicrob Chemother* 2007; **60**: 613–18.
 - 12 Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. *Antimicrob Agents Chemother* 2010; **54**: 184–90.
 - 13 Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. *J Infect* 1996; **33**: 23–32.
 - 14 Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. *Ann Intern Med* 1988; **108**: 88–100.
 - 15 Ness MJ, Vaughan WP, Woods GL. *Candida* antigen latex test for detection of invasive candidiasis in immunocompromised patients. *J Infect Dis* 1989; **159**: 495–502.
 - 16 Clancy CJ, Nguyen MH. Finding the 'missing 50%' of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. *Clin Infect Dis* 2013; **56**: 1284–92.
 - 17 Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev* 2007; **20**: 133–63.
 - 18 Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. *J Antimicrob Chemother* 2010; **65**: 1042–51.
 - 19 Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant blood-stream isolates of *Candida glabrata*. *J Clin Microbiol* 2012; **50**: 1199–203.
 - 20 Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T et al. FKS mutations and elevated echinocandin MIC values among *Candida glabrata* isolates from U.S. population-based surveillance. *Antimicrob Agents Chemother* 2010; **54**: 5042–7.
 - 21 Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans *Candida* spp. *Crit Care Med* 2008; **36**: 2034–9.
 - 22 van Hal S, Chen SC, Sorrell TC, Ellis DH, Slavin MA, Marriott DJ. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre YeastOne for *Candida albicans*: a prospective observational cohort study. *J Antimicrob Chemother* 2014; **69**: 2210–4.
 - 23 Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004–2008. *Diagn Microbiol Infect Dis* 2012; **74**: 323–31.
 - 24 Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. *Crit Care* 2010; **14**: R222.
 - 25 Perfect JR. Fungal diagnosis: how do we do it and can we do better? *Curr Med Res Opin* 2013; **29**(Suppl 4): 3–11.
 - 26 Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR et al. beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. *PLoS ONE* 2012; **7**: e42282.
 - 27 Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. *J Clin Microbiol* 2007; **45**: 380–5.
 - 28 Lau A, Halliday C, Chen SC, Playford EG, Stanley K, Sorrell TC. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. *J Clin Microbiol* 2010; **48**: 811–16.
 - 29 Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. *J Clin Microbiol* 2011; **49**: 665–70.
 - 30 Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. *Candida* colonization and subsequent infections in critically ill surgical patients. *Ann Surg* 1994; **220**: 751–8.
 - 31 Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. *Crit Care Med* 2004; **32**: 2443–9.
 - 32 Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer* 2008; **112**: 2493–9.
 - 33 Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob*

- Agents Chemother* 2011; **55**: 532–8.
- 34 Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M *et al.* Antibiotic exposure as a risk factor for fluconazole-resistant *Candida* bloodstream infection. *Antimicrob Agents Chemother* 2012; **56**: 2518–23.
- 35 Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R *et al.* Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis* 2013; **56**: 1724–32.
- 36 Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT *et al.* *Candida* spp. with acquired echinocandin resistance, France, 2004–2010. *Emerg Infect Dis* 2012; **18**: 86–90.
- 37 Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008. *J Hosp Infect* 2010; **76**: 46–51.
- 38 Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. *J Clin Microbiol* 2013; **51**: 2571–81.
- 39 Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR *et al.* Clinical breakpoints for the echinocandins and *Candida* revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. *Drug Resist Updat* 2011; **14**: 164–76.
- 40 Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO *et al.* Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. *Clin Infect Dis* 1996; **23**: 964–72.
- 41 Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE *et al.* A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. *N Engl J Med* 1994; **331**: 1325–30.
- 42 Phillips P, Shafran S, Garber G, Rotstein C, Smail F, Fong I *et al.* Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. *Eur J Clin Microbiol Infect Dis* 1997; **16**: 337–45.
- 43 Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. *Mycoses* 2001; **44**: 125–35.
- 44 Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. *Mayo Clin Proc* 2008; **83**: 1011–21.
- 45 Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH *et al.* Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. *Lancet* 2005; **366**: 1435–42.
- 46 Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. *Pediatrics* 2007; **119**: 772–84.
- 47 Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D *et al.* Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. *Pediatr Infect Dis J* 1996; **15**: 1107–12.
- 48 Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. *Cochrane Database Syst Rev* 2010; (17) CD006343.
- 49 Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smetana J *et al.* Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002; **347**: 2020–9.
- 50 Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D *et al.* Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet* 2007; **369**: 1519–27.
- 51 Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D *et al.* Anidulafungin versus fluconazole for invasive candidiasis. *N Engl J Med* 2007; **356**: 2472–82.
- 52 Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ *et al.* Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 2007; **45**: 883–93.
- 53 Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE *et al.* Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. *Pharmacoepidemiol Drug Saf* 2007; **16**: 919–27.
- 54 Fernandez-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, Puig-Asensio M *et al.* Initial Use of Echinocandins Does Not Negatively Influence Outcome in *Candida* parapsilosis Bloodstream Infection: A Propensity Score Analysis. *Clin Infect Dis* 2014; **58**: 1413–21.
- 55 Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasonndh T *et al.* Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. *Pediatr Infect Dis J* 2008; **27**: 820–6.
- 56 Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. *J Trop Pediatr* 2012; **58**: 25–30.
- 57 Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH *et al.* Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis* 2012; **54**: 1110–22.
- 58 Lashof AM, Vogelaers D. Does a patient-level quantitative review of randomized trials on the outcomes in candidemia and invasive candidiasis need to include all patients? *Clin Infect Dis* 2013; **56**: 1514–15.
- 59 Anaissie E, Nucci M. Far-reaching conclusions based on weak and missing data. *Clin Infect Dis* 2012; **55**: 890–3.

- 60 Cisneros JM, Neth O, Pachon J. Selection bias in Andes *et al. Clin Infect Dis* 2012; **55**: 893–4.
- 61 Mills EJ, Perri D, Cooper C, Nachega JB, Wu P, Tleyjeh I *et al.* Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. *Ann Clin Microbiol Antimicrob* 2009; **8**: 23.
- 62 Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O *et al.* ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect* 2012; **18**(Suppl 7): 68–77.
- 63 Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. *Crit Care* 2011; **15**: R253.
- 64 Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R *et al.* Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. *Clin Microbiol Infect* 2014; **20**: O245–54.
- 65 Mochizuki K, Sawada A, Suemori S, Kawakami H, Niwa Y, Kondo Y *et al.* Intraocular penetration of intravenous micafungin in inflamed human eyes. *Antimicrob Agents Chemother* 2013; **57**: 4027–30.
- 66 Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. *Clin Infect Dis* 1997; **24**: 375–80.
- 67 Legrand F, Lecuit M, Dupont B, Bellaton E, Huerre M, Rohrlach PS *et al.* Adjuvant corticosteroid therapy for chronic disseminated candidiasis. *Clin Infect Dis* 2008; **46**: 696–702.
- 68 De CN, Mazoyer E, Porcher R, Raffoux E, Suarez F, Ribaud P *et al.* Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. *Clin Microbiol Infect* 2012; **18**: E185–7.
- 69 Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D *et al.* Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. *Haematologica* 2002; **87**: 535–41.
- 70 Chaussade H, Bastides F, Lissandre S, Blouin P, Bailly E, Chandener J *et al.* Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. *J Antimicrob Chemother* 2012; **67**: 1493–5.
- 71 Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. *Br J Haematol* 2005; **131**: 287–300.
- 72 Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr *et al.* Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009; **48**: 503–35.
- 73 Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. *Expert Rev Anti Infect Ther* 2005; **3**: 775–85.
- 74 Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST *et al.* Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. *J Clin Microbiol* 2004; **42**: 5950–3.
- 75 Flattery AM, Hickey E, Gill CJ, Powles MA, Misura AS, Galgoczi AM *et al.* Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. *Antimicrob Agents Chemother* 2011; **55**: 3491–7.
- 76 Kang CI, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R. Anidulafungin treatment of candidal central nervous system infection in a murine model. *Antimicrob Agents Chemother* 2009; **53**: 3576–8.
- 77 Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. *Clin Infect Dis* 2003; **37**: 728–32.
- 78 Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C *et al.* Ocular manifestations of candidemia. *Clin Infect Dis* 2011; **53**: 262–8.
- 79 Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. *Clin Infect Dis* 1995; **20**: 657–64.
- 80 Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, Sopena B, de la Fuente J, Ocampo A *et al.* Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. *Clin Infect Dis* 1998; **27**: 1130–3.
- 81 Riddell J, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. *Clin Infect Dis* 2011; **52**: 648–53.
- 82 Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. *Clin Infect Dis* 2001; **33**: 523–30.
- 83 Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. *Diagn Microbiol Infect Dis* 2012; **73**: 89–93.
- 84 Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G *et al.* Caspofungin for the treatment of less common forms of invasive candidiasis. *J Antimicrob Chemother* 2007; **60**: 363–9.
- 85 Sili U, Yilmaz M, Ferhanoglu B, Mert A. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. *Clin Infect Dis* 2007; **45**: 897–8.
- 86 Neofytos D, Huprikar S, Reboli A, Schuster M, Azie N, Franks B *et al.* Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance(R) registry. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 135–41.
- 87 Gamaletsou MN, Kontoyiannis DP, Sipsas NV, Moriyama B, Alexander E, Roilides E *et al.* Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970–2011). *Clin Infect Dis* 2012; **55**: 1338–51.
- 88 Dutronc H, Dauchy FA, Cazanave C, Rougie C, Lafarie-Castet S, Couprie B *et al.* Candida prosthetic infections: case series and literature review. *Scand J Infect Dis* 2010; **42**: 890–5.
- 89 Kathresal A, Biundo J, Blais CM, Morse S, Reisin E. A rare case of Candida arthritis in a hemodialysis patient. *Am J Med Sci* 2008; **336**: 437–40.
- 90 Lerch K, Kalteis T, Schubert T, Lehn N, Grifka J. Prosthetic joint infections with osteomyelitis due to Candida albicans. *Mycoses* 2003; **46**: 462–6.
- 91 Baddley JW, Benjamin DK Jr, Patel M, Miro J, Athan E, Barsic B *et al.* Candida infective endocarditis. *Eur J Clin Microbiol Infect Dis* 2008; **27**: 519–29.

- 92 Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I *et al.* Diagnosis, management and outcome of Candida endocarditis. *Clin Microbiol Infect* 2012; **18**: E99–109.
- 93 Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V *et al.* Candida infective endocarditis: report of 15 cases from a prospective multicenter study. *Medicine (Baltimore)* 2009; **88**: 160–8.
- 94 Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. *Chest* 2002; **122**: 302–10.
- 95 De Rosa FG, D'Avolio A, Corcione S, Baietto L, Raviolo S, Centofanti P *et al.* Anidulafungin for Candida glabrata infective endocarditis. *Antimicrob Agents Chemother* 2012; **56**: 4552–3.
- 96 Talarmin JP, Boutoille D, Tattevin P, Abgueguen P, Ansart S, Roblot F *et al.* Candida endocarditis: role of new antifungal agents. *Mycoses* 2009; **52**: 60–6.
- 97 Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. *Medicine (Baltimore)* 2011; **90**: 237–49.
- 98 Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E *et al.* Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. *Antimicrob Agents Chemother* 2005; **49**: 3317–24.
- 99 Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. *Antimicrob Agents Chemother* 2008; **52**: 3022–8.
- 100 Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. *J Pediatr* 1992; **120**: 987–93.
- 101 Wade KC, Benjamin DK Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B *et al.* Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. *Pediatr Infect Dis J* 2009; **28**: 717–23.
- 102 Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G *et al.* Fluconazole loading dose pharmacokinetics and safety in infants. *Pediatr Infect Dis J* 2011; **30**: 375–8.
- 103 Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X *et al.* Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *Antimicrob Agents Chemother* 2004; **48**: 2166–72.
- 104 Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E *et al.* Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. *Antimicrob Agents Chemother* 2002; **46**: 2554–63.
- 105 Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. *Antimicrob Agents Chemother* 2005; **49**: 5092–8.
- 106 Saez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A *et al.* Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. *Antimicrob Agents Chemother* 2009; **53**: 869–75.
- 107 Benjamin DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R *et al.* Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. *Antimicrob Agents Chemother* 2006; **50**: 632–8.
- 108 Cohen-Wolkowicz M, Benjamin DK Jr, Piper L, Cheifetz IM, Moran C, Liu P *et al.* Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. *Clin Pharmacol Ther* 2011; **89**: 702–7.
- 109 Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A *et al.* Population pharmacokinetics of micafungin in neonates and young infants. *Antimicrob Agents Chemother* 2010; **54**: 2633–7.
- 110 Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M *et al.* Candidemia surveillance in Iowa: emergence of echinocandin resistance. *Diagn Microbiol Infect Dis* 2014; **79**: 205–8.
- 111 Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. *Microbiology* 1997; **143**(Pt 2): 405–16.
- 112 Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. *Antimicrob Agents Chemother* 2005; **49**: 783–7.
- 113 Fonseca E, Silva S, Rodrigues CF, Alves CT, Azeredo J, Henriques M. Effects of fluconazole on Candida glabrata biofilms and its relationship with ABC transporter gene expression. *Biofouling* 2014; **30**: 447–57.
- 114 Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. *Antimicrob Agents Chemother* 2005; **49**: 668–79.
- 115 Ferrari S, Sanguinetti M, De BF, Torelli R, Posteraro B, Vandeputte P *et al.* Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. *Antimicrob Agents Chemother* 2011; **55**: 1852–60.
- 116 Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. *Clin Infect Dis* 2001; **32**: 50–62.
- 117 Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS *et al.* A meta-analysis of medical versus surgical therapy for Candida endocarditis. *J Infect* 2005; **51**: 230–47.
- 118 Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin DS, Fadda G *et al.* In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. *Antimicrob Agents Chemother* 2011; **55**: 3031–5.
- 119 Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. *Antimicrob Agents Chemother* 2002; **46**: 1773–80.
- 120 Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR *et al.* In vitro activity of caspofungin against Candida albicans biofilms. *Antimicrob Agents Chemother* 2002; **46**: 3591–6.
- 121 Oude Lashof AM, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. *Eur J Clin Microbiol Infect Dis* 2003; **22**: 43–8.

- 122 Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP *et al.* Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009; **49**: 1–45.
- 123 Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, de Ruiz Perez PM, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in *Candida* spp. bloodstream infections. *J Antimicrob Chemother* 2013; **68**: 206–13.
- 124 Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE *et al.* Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. *Clin Infect Dis* 1995; **21**: 994–6.
- 125 Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against *Candida albicans* biofilms. *Antimicrob Agents Chemother* 2008; **52**: 2242–3.
- 126 Ramage G, Jose A, Sherry L, Lappin DF, Jones B, Williams C. Liposomal amphotericin B displays rapid dose-dependent activity against *Candida albicans* biofilms. *Antimicrob Agents Chemother* 2013; **57**: 2369–71.
- 127 Uzun O, Asciglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. *Clin Infect Dis* 2001; **32**: 1713–17.
- 128 Nucci M, Colombo AL. Risk factors for breakthrough candidemia. *Eur J Clin Microbiol Infect Dis* 2002; **21**: 209–11.
- 129 Nagao M, Saito T, Doi S, Hotta G, Yamamoto M, Matsumura Y *et al.* Clinical characteristics and risk factors of ocular candidiasis. *Diagn Microbiol Infect Dis* 2012; **73**: 149–52.
- 130 Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. *Medicine (Baltimore)* 2003; **82**: 187–202.
- 131 Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ *et al.* A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. *Clin Infect Dis* 2009; **48**: 1676–84.
- 132 Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin-Hong P *et al.* Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. *BMC Infect Dis* 2014; **14**: 97.
- 133 Kwon-Chung KJ, Boekhout T, Wickes BL, Fell JW. Systematics of the Genus *Cryptococcus* and its type species *C. neoformans*. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, eds. *Cryptococcus – From Human Pathogen to Model Yeast*. Washington, DC: ASM Press; 2011; 3–15.
- 134 Chayakulkeeree M, Perfect JR. Cryptococcosis. *Infect Dis Clin North Am* 2006; **20**: 507–44, v–vi.
- 135 Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S *et al.* *Cryptococcus neoformans-Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. *Antimicrob Agents Chemother* 2012; **56**: 5898–906.
- 136 Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F *et al.* *Cryptococcus neoformans-Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. *Antimicrob Agents Chemother* 2012; **56**: 3107–13.
- 137 Ellis D, Sorrell T, Chen S. Impact of antifungal resistance in Australia. *Microbiol Aust* 2007; **28**: 171–3.
- 138 Sorrell TC, Chen SC, Ruma P, Meyer W, Pfeiffer TJ, Ellis DH *et al.* Concordance of clinical and environmental isolates of *Cryptococcus neoformans* var. *gattii* by random amplification of polymorphic DNA analysis and PCR fingerprinting. *J Clin Microbiol* 1996; **34**: 1253–60.
- 139 Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ *et al.* Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2010; **50**: 291–322.
- 140 Chen SC, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D *et al.* Clinical manifestations of *Cryptococcus gattii* infection: determinants of neurological sequelae and death. *Clin Infect Dis* 2012; **55**: 789–98.
- 141 Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N *et al.* Antifungal Therapy and Management of Complications of Cryptococcosis due to *Cryptococcus gattii*. *Clin Infect Dis* 2013; **57**: 543–51.
- 142 Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH *et al.* Combination antifungal therapy for cryptococcal meningitis. *N Engl J Med* 2013; **368**: 1291–302.
- 143 Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J *et al.* Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. *AIDS* 1997; **11**: 1463–71.
- 144 Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javalay K *et al.* Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. *Clin Infect Dis* 2010; **51**: 225–32.
- 145 O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ *et al.* Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. *J Infect Dis* 2013; **208**: 351–61.
- 146 Chang CC, Dorasamy AA, Gosnell BI, Elliott JH, Spelman T, Omarjee S *et al.* Clinical and mycological predictors of Cryptococcosis-associated Immune reconstitution inflammatory syndrome (C-IRIS). *AIDS* 2013; **27**: 2089–99.
- 147 Anekthananon T, Manosuthi W, Chetchoisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W *et al.* Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. *Int J STD AIDS* 2011; **22**: 665–70.

- 148 Australian categorisation system for prescribing medicines in pregnancy: Australian Government, Department of Health, Therapeutic Goods Administration; 2014. [cited 2014 Sep 10]. Available from URL: <http://www.tga.gov.au/hp/medicines-pregnancy-categorisation.htm>
- 149 Chimalizeni Y, Tickell D, Connell T. Evidence behind the WHO guidelines: hospital care for children: what is the most appropriate anti-fungal treatment for acute cryptococcal meningitis in children with HIV? *J Trop Pediatr* 2010; **56**: 4–12.
- 150 Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ *et al.* Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. *Clin Infect Dis* 2001; **33**: 690–9.
- 151 Dromer F, Mathoulin S, Dupont B, Brugiére O, Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. *Clin Infect Dis* 1996; **22**(Suppl 2): S154–60.
- 152 Graybill JR, Sobel J, Saag M, van der Horst C, Powderly W, Cloud G *et al.* Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. *Clin Infect Dis* 2000; **30**: 47–54.
- 153 Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, Sinha A *et al.* Cryptococcal meningitis (*C. neoformans* var. *gattii*) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. *Q J Med* 1994; **87**: 343–9.
- 154 Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. Visual loss in immunocompetent patients with *Cryptococcus neoformans* var. *gattii* meningitis. *Trans R Soc Trop Med Hyg* 1997; **91**: 44–9.
- 155 Fessler RD, Sobel J, Guyot L, Crane L, Vazquez J, Szuba MJ *et al.* Management of elevated intracranial pressure in patients with Cryptococcal meningitis. *J Acquir Immune Defic Syndr Hum Retroviro* 1998; **17**: 137–42.
- 156 van Gemert HM, Vermeulen M. Treatment of impaired consciousness with lumbar punctures in a patient with cryptococcal meningitis and AIDS. *Clin Neurol Neurosurg* 1991; **93**: 257–8.
- 157 Arriada N, Sotelo J. Review: treatment of hydrocephalus in adults. *Surg Neurol* 2002; **58**: 377–84.
- 158 Calvo A, Hernandez P, Spagnuolo E, Johnston E. Surgical treatment of intracranial hypertension in encephalic cryptococcosis. *Br J Neurosurg* 2003; **17**: 450–5.
- 159 Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A *et al.* Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. *J Infect Dis* 2004; **189**: 2185–91.
- 160 Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A *et al.* Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. *AIDS* 2012; **26**: 1105–13.
- 161 Lane M, McBride J, Archer J. Steroid responsive late deterioration in *Cryptococcus neoformans* variety *gattii* meningitis. *Neurology* 2004; **63**: 713–14.
- 162 Newton PN, Thai H, Tip NQ, Short JM, Chierakul W, Rajanuwong A *et al.* A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. *Clin Infect Dis* 2002; **35**: 769–72.
- 163 Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, Torre-Cisneros J *et al.* Voriconazole treatment for less-common, emerging, or refractory fungal infections. *Clin Infect Dis* 2003; **36**: 1122–31.
- 164 Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S *et al.* Activity of posaconazole in the treatment of central nervous system fungal infections. *J Antimicrob Chemother* 2005; **56**: 745–55.
- 165 Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K *et al.* An immune reconstitution syndrome-like illness associated with *Cryptococcus neoformans* infection in organ transplant recipients. *Clin Infect Dis* 2005; **40**: 1756–61.
- 166 Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC *et al.* Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. *Lancet Infect Dis* 2010; **10**: 791–802.
- 167 Chang CC, Omarjee S, Lim A, Spelman T, Gosnell BI, Carr WH *et al.* Chemokine levels and chemokine receptor expression in blood and the CSF of HIV-infected patients with cryptococcal meningitis and C-IRIS. *J Infect Dis* 2013; **208**: 1604–12.
- 168 Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O *et al.* ESCMID/ECMM Joint Clinical Guideline for the Diagnosis and Management of Rare Invasive Yeast Infections. *Clin Microbiol Infect* 2013.
- 169 Henrich TJ, Marty FM, Milner DA Jr, Thorner AR. Disseminated *Geotrichum candidum* infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. *Transpl Infect Dis* 2009; **11**: 458–62.
- 170 Ng KP, Soo-Hoo TS, Koh MT, Kwan PW. Disseminated *Geotrichum* infection. *Med J Malaysia* 1994; **49**: 424–6.
- 171 Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O *et al.* Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. *Rev Argent Microbiol* 2011; **43**: 176–85.
- 172 Taj-Aldeen SJ, Doiphode SH, Han XY. Kodamaea (*Pichia*) *ohmeri* fungaemia in a premature neonate. *J Med Microbiol* 2006; **55**: 237–9.
- 173 De Barros JD, Do Nascimento SM, De Araujo FJ, Braz RF, Andrade VS, Theelen B *et al.* Kodamaea (*Pichia*) *ohmeri* fungemia in a pediatric patient admitted in a public hospital. *Med Mycol* 2009; **47**: 775–9.
- 174 Santino I, Bono S, Borruso L, Bove M, Cialdi E, Martinelli D *et al.* Kodamaea *ohmeri* isolate from two immunocompromised patients: first report in Italy. *Mycoses* 2013; **56**: 179–81.
- 175 Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ. Fluconazole-resistant Kodamaea *ohmeri* fungemia associated with cellulitis: case report and review

- of the literature. *Int J Infect Dis* 2009; **13**: e493–7.
- 176 Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of *Rhodotorula* infection in haematological patients. *Mycoses* 2011; **54**: 318–24.
- 177 Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against *rhodotorula* species. *J Clin Microbiol* 2005; **43**: 476–8.
- 178 Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. *Clin Infect Dis* 2006; **42**: 753–7.
- 179 Suzuki K, Nakase K, Kyo T, Kohara T, Sugawara Y, Shibasaki T *et al.* Fatal *Trichosporon* fungemia in patients with hematologic malignancies. *Eur J Haematol* 2010; **84**: 441–7.